Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
3.960
-0.030 (-0.75%)
At close: May 16, 2025, 4:00 PM
4.030
+0.070 (1.77%)
After-hours: May 16, 2025, 5:20 PM EDT

Astria Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Selling, General & Admin
36.1635.2526.0319.7315.1512.36
Upgrade
Research & Development
88.2476.3141.833.7815.2125.08
Upgrade
Operating Expenses
124.4111.5667.8353.530.3637.44
Upgrade
Operating Income
-124.4-111.56-67.83-53.5-30.36-37.44
Upgrade
Interest & Investment Income
16.4717.3610.21.720.120.24
Upgrade
Other Non Operating Income (Expenses)
-0.1-0.06-0.06-0.06-0.06-0.1
Upgrade
EBT Excluding Unusual Items
-108.04-94.26-57.69-51.83-30.3-37.3
Upgrade
Pretax Income
-108.04-94.26-72.89-51.83-194.91-37.3
Upgrade
Net Income
-108.04-94.26-72.89-51.83-194.91-37.3
Upgrade
Preferred Dividends & Other Adjustments
----24.44-
Upgrade
Net Income to Common
-108.04-94.26-72.89-51.83-219.35-37.3
Upgrade
Shares Outstanding (Basic)
5856301593
Upgrade
Shares Outstanding (Diluted)
5856301593
Upgrade
Shares Change (YoY)
59.04%86.44%106.03%63.81%191.81%63.87%
Upgrade
EPS (Basic)
-1.88-1.68-2.42-3.55-24.58-12.20
Upgrade
EPS (Diluted)
-1.88-1.68-2.42-3.55-24.58-12.20
Upgrade
Free Cash Flow
-96.46-81.54-68.47-43.62-30.17-32.52
Upgrade
Free Cash Flow Per Share
-1.68-1.45-2.27-2.98-3.38-10.63
Upgrade
EBITDA
------37.41
Upgrade
D&A For EBITDA
-----0.03
Upgrade
EBIT
-124.4-111.56-67.83-53.5-30.36-37.44
Upgrade
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q